Generic Licensing: the Only Path Through the Maze of Gilead and US Patents that Achieves Access to Affordable PrEP

CDC and AIDS service organizations should not be in the unenviable position of having to rely on continued high prices charged by Gilead to get dimes on the dollar of what should otherwise be appropriated by Congress on a sustainable basis, writes Professor Brook Baker in his latest opinion piece for the Health GAP blog.